Increased Matrix Metalloproteinase (MMPs) Levels Do Not Predict Disease Severity or Progression in Emphysema

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  D'Armiento, Jeanine M ^a   Goldklang, Monica P ^a   Hardigan, Andrew A ^b   Geraghty, Patrick ^b   Roth, Michael D ^c   Connett, John E ^d   Wise, Robert A ^e   Sciurba, Frank C ^f   Scharf, Steven M ^g   Thankachen, Jincy ^a   Islam, Monirul ^a   Ghio, Andrew J ^h   Foronjy, Robert F ^b  

^a NewYork Presbyterian Hospital   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^h U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTICLE; BLOOD ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EMPHYSEMA; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG FUNCTION; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; UPREGULATION;

ADULT; AGED; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE PROGRESSION; EMPHYSEMA; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SMOKING; TISSUE INHIBITOR OF METALLOPROTEINASE-1; YOUNG ADULT;

EID: 84874174967     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056352     Document Type: Article

References (37)

1. Shiomi T, Okada Y, Foronjy R, Schiltz J, Jaenish R,et al. (2001) Emphysematous Changes Are Caused By Degradation Of Type III Collagen In Transgenic Mice Expressing MMP-1. Exp Lung Res.
2. Hu J, Van den Steen PE, Sang QX, Opdenakker G, (2007) Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 6: 480-498.
3. Houghton AM, Quintero PA, Perkins DL, Kobayashi DK, Kelley DG, et al. (2006) Elastin fragments drive disease progression in a murine model of emphysema. J Clin Invest 116: 753-759.
4. Finlay GA, O'Driscoll L, Russell KJ, D'Arcy EM, Masterson JB, et al. (1997) Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. American Journal Respiratory Critical Care Medicine 156: 240-247.
5. Ohnishi K, Takagi M, Kurokawa Y, Satomi S, Konttinen YT, (1998) Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest 78: 1077-1087.
6. Imai K, Dalal SS, Chen ES, Downey R, Schulman LL, et al. (2001) Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. Am J Respir Crit Care Med 163: 786-791.
7. Segura-Valdez L, Pardo A, Gaxiola M, Uhal BD, Becerril C, et al. (2000) Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 117: 684-694.
8. Foronjy RF, Okada Y, Cole R, D'Armiento J, (2003) Progressive adult-onset emphysema in transgenic mice expressing human MMP-1 in the lung. Am J Physiol Lung Cell Mol Physiol 284: L727-737.
9. Russell RE, Culpitt SV, DeMatos C, Donnelly L, Smith M, et al. (2002) Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 26: 602-609.
10. Atkinson JJ, Lutey BA, Suzuki Y, Toennies HM, Kelley DG, et al. (2011) The role of matrix metalloproteinase-9 in cigarette smoke-induced emphysema. Am J Respir Crit Care Med 183: 876-884.
11. Foronjy R, Nkyimbeng T, Wallace A, Thankachen J, Okada Y, et al. (2008) Transgenic expression of matrix metalloproteinase-9 causes adult-onset emphysema in mice associated with the loss of alveolar elastin. Am J Physiol Lung Cell Mol Physiol 294: L1149-1157.
12. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD, (1997) Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 277: 2002-2004.
13. Chaudhuri R, McSharry C, Brady J, Donnelly I, Grierson C,et al. (2012) Sputum matrix metalloproteinase-12 in patients with chronic obstructive pulmonary disease and asthma: Relationship to disease severity. J Allergy Clin Immunol.
14. Hunninghake GM, Cho MH, Tesfaigzi Y, Soto-Quiros ME, Avila L, et al. (2009) MMP12, lung function, and COPD in high-risk populations. N Engl J Med 361: 2599-2608.
15. Haq I, Lowrey GE, Kalsheker N, Johnson SR, (2011) Matrix metalloproteinase-12 (MMP-12) SNP affects MMP activity, lung macrophage infiltration and protects against emphysema in COPD. Thorax 66: 970-976.
16. Roth MD, Connett JE, D'Armiento JM, Foronjy RF, Friedman PJ, et al. (2006) Feasibility of retinoids for the treatment of emphysema study. Chest 130: 1334-1345.
17. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 152: 1107-1136.
18. Hankinson JL, Odencrantz JR, Fedan KB, (1999) Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 159: 179-187.
19. Crapo RO, Morris AH, (1981) Standardized single breath normal values for carbon monoxide diffusing capacity. Am Rev Respir Dis 123: 185-189.
20. Jones PW, Quirk FH, Baveystock CM, Littlejohns P, (1992) A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 145: 1321-1327.
21. Boedeker KL, McNitt-Gray MF, Rogers SR, Truong DA, Brown MS, et al. (2004) Emphysema: effect of reconstruction algorithm on CT imaging measures. Radiology 232: 295-301.
22. Muller NL, Staples CA, Miller RR, Abboud RT, (1988) "Density mask". An objective method to quantitate emphysema using computed tomography. Chest 94: 782-787.
23. D'Armiento JM, Scharf SM, Roth MD, Connett JE, Ghio A, et al. (2009) Eosinophil and T cell markers predict functional decline in COPD patients. Respir Res 10: 113.
24. Mandl I, Maclennan JD, Howes EL, (1953) Isolation and characterization of proteinase and collagenase from Cl. histolyticum. J Clin Invest 32: 1323-1329.
25. Moore S, Stein WH, (1948) Chromatography of amino acids; colorimetric ninhydrin method for analysis of the effluent. Fed Proc 7: 174.
26. Feinstein G, Kupfer A, Sokolovsky M, (1973) N-acetyl-(L-Ala) 3-p-nitroanilide as a new chromogenic substrate for elastase. Biochem Biophys Res Commun 50: 1020-1026.
27. Bieth J, Spiess B, Wermuth CG, (1974) The synthesis and analytical use of a highly sensitive and convenient substrate of elastase. Biochem Med 11: 350-357.
28. Croxton TL, Weinmann GG, Senior RM, Wise RA, Crapo JD, et al. (2003) Clinical research in chronic obstructive pulmonary disease: needs and opportunities. Am J Respir Crit Care Med 167: 1142-1149.
29. Ilumets H, Rytila P, Demedts I, Brusselle GG, Sovijarvi A, et al. (2007) Matrix metalloproteinases-8,-9 and-12 in smokers and patients with stage 0 COPD. Int J Chron Obstruct Pulmon Dis 2: 369-379.
30. Navratilova Z, Zatloukal J, Kriegova E, Kolek V, Petrek M (2012) Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitor of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease. Respirology.
31. Zucker S, Doshi K, Cao J, (2004) Measurement of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMP) in blood and urine: potential clinical applications. Adv Clin Chem 38: 37-85.
32. Rajendrasozhan S, Chung S, Sundar IK, Yao H, Rahman I, (2010) Targeted disruption of NF-{kappa}B1 (p50) augments cigarette smoke-induced lung inflammation and emphysema in mice: a critical role of p50 in chromatin remodeling. Am J Physiol Lung Cell Mol Physiol 298: L197-209.
33. Huang YL, Chuang CY, Sung FC, Chen CY, (2008) Thioredoxin overexpression modulates remodeling factors in stress responses to cigarette smoke. J Toxicol Environ Health A 71: 1490-1498.
34. Ito I, Nagai S, Handa T, Muro S, Hirai T, et al. (2005) Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med 172: 1378-1382.
35. Lee SY, Kim MJ, Kang HG, Yoo SS, Choi YY, et al. (2010) Polymorphisms in matrix metalloproteinase-1,-9 and-12 genes and the risk of chronic obstructive pulmonary disease in a Korean population. Respiration 80: 133-138.
36. Wallace AM, Sandford AJ, English JC, Burkett KM, Li H, et al. (2008) Matrix metalloproteinase expression by human alveolar macrophages in relation to emphysema. Copd 5: 13-23.
37. Joos L, He JQ, Shepherdson MB, Connett JE, Anthonisen NR, et al. (2002) The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet 11: 569-576.